Skip to main content
SpringerLink
Log in

Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Existence and cause of thyroid stunning was controversially discussed for decades but the underlying mechanism remains unclear. Numerous studies describe thyroid stunning in radioiodine-131 therapy (RIT) of differentiated thyroid carcinoma. However, there are no studies evaluating thyroid stunning in benign thyroid diseases caused by the radioiodine uptake test (RIUT). Therefore, the influence of pre-therapeutic tracer radiation dose on therapeutic iodine-131 uptake was evaluated retrospectively.

Methods

A total of 914 RIT patients were included. Exclusion criteria were anti-thyroid drugs, pre- and/or intra-therapeutic effective half-lives (EHL) beyond 8.04 days and externally performed RIUT or 24 h RIUT. All patients received RIUT 1 week before RIT. Thyroid volume was estimated via ultrasound. Tracer radiation dose to the thyroid was calculated retrospectively. The dependence of changes in the pre-therapeutic to the therapeutic extrapolated-maximum-131I-uptake (EMU) from the dose in RIUT was evaluated statistically.

Results

EMU in RIUT ranged from 0.10 to 0.82 (median: 0.35) and EMU in RIT ranged from 0.10 to 0.74 (median: 0.33). Averaged over the whole cohort the therapeutic EMU decreased significantly (2.3% per Gray intra-thyroidal tracer radiation dose). A disease-specific evaluation showed dose-dependent thyroid stunning from 1.2% per Gray in solitary toxic nodules (n = 327) to 21% per Gray in goiters (n = 135) which was significant for the subgroups of disseminated autonomies (n = 114), multifocal autonomies (n = 178) and goiters (p < 0.05) but not for Graves’ diseases (n = 160) and solitary toxic nodules (p > 0.05).

Conclusions

The presented data indicate for the first time a significant dependence of pre-therapeutic radiation dose on thyroid stunning in goiter and disseminated and multifocal autonomy. To achieve the desired intra-thyroidal radiation dose, RIT activity should be adapted depending on the dose in RIUT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. R. Lorenz, A. Buck, C. Reiners, In-patient nuclear medicine therapy in Germany from 2010 to 2012 – analysis of structured quality reports. Nuklearmedizin 54, 61–68 (2015)

    Article  CAS  PubMed  Google Scholar 

  2. M. Freesmeyer, F. Gühne, C. Kühnel, T. Opfermann, T. Winkens, A. Werner Determination of effective half-life of 131I in patients with differentiated thyroid carcinoma: comparison of cystatin C and creatinine-based estimation of renal function. Endocrine (2018). https://doi.org/10.1007/s12020-018-1800-4

  3. O. Dohan, A. de la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C.S. Ginter, N. Carrasco, The sodium/iodine symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev. 24, 48–77 (2003)

    Article  CAS  PubMed  Google Scholar 

  4. E. Bell, F. Grünwald. Radiojodtherapie bei Benignen und Malignen Schilddrüsenerkrankungen (Springer-Verlag Berlin Heidelberg, New York, 1999).

    Google Scholar 

  5. R.W. Rawson, J.E. Rall, W. Peacock, Limitations in the treatment of cancer of the thyroid with radioactive iodine. Trans. Assoc. Am. Physicians 64, 179–198 (1951)

    CAS  PubMed  Google Scholar 

  6. W. Brenner, Is thyroid stunning a real phenomenon or just fiction? J. Nucl. Med. 43, 835–836 (2002)

    PubMed  Google Scholar 

  7. A.J. Coakley, Thyroid stunning. Eur. J. Nucl. Med. 25, 203–204 (1998)

    Article  CAS  PubMed  Google Scholar 

  8. H.Q. Dam, S.M. Kim, H.C. Lin, C.M. Intenzo, 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology 232, 527–533 (2004)

    Article  PubMed  Google Scholar 

  9. I.R. McDougall, A. Iagaru, Thyroid stunning: fact or fiction? Semin. Nucl. Med. 41, 105–112 (2011)

    Article  PubMed  Google Scholar 

  10. S.P. Cholewinski, K.S. Yoo, P.S. Klieger, R.E. O’Mara, Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J. Nucl. Med. 41, 1198–1202 (2000)

    CAS  PubMed  Google Scholar 

  11. M. Filesi, M. Colandrea, T. Montesano, R. D’Apollo, G. Ronga, Thyroid stunning in clinical practice: is it a real problem? Minerva Endocrinol. 34, 29–36 (2009)

    CAS  PubMed  Google Scholar 

  12. J.M. Woolfenden, Thyroid stunning revisited. J. Nucl. Med. 47, 1403–1404 (2006)

    CAS  PubMed  Google Scholar 

  13. J.E. Kalinyak, I.R. McDougall, Whole-body scanning with radionuclides of iodine, and the controversy of “thyroid stunning“. Nucl. Med. Commun. 25, 883–889 (2004)

    Article  PubMed  Google Scholar 

  14. S. Walrand, M. Hesse, F. Jamar, Statistical and radiobiological analysis of the so-called thyroid stunning. EJNMMI Res. 5, 67 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. M. Lassmann, M. Luster, H. Hänscheid, C. Reiners, Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J. Nucl. Med. 45, 619–625 (2004)

    PubMed  Google Scholar 

  16. L.F. Morris, A.D. Waxman, G.D. Braunstein, Thyroid stunning. Thyroid 13, 333–340 (2003).

    Article  PubMed  Google Scholar 

  17. J.P. Muratet, A. Daver, J.F. Minier, F. Larra, Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J. Nucl. Med. 39, 1546–1550 (1998)

    CAS  PubMed  Google Scholar 

  18. P. Postgård, J. Himmelman, U. Lindencrona, N. Bhogal, D. Wiberg, G. Berg, S. Jansson, E. Nyström, E. Forssell-Aronsson, M. Nilsson, Stunning of iodide transport by 131I irradiation in cultured thyroid epithelial cells. J. Nucl. Med. 43, 828–834 (2002)

    PubMed  Google Scholar 

  19. M.M. Nordén, F. Larsson, S. Tedelind, T. Carlsson, C. Lundh, E. Forssell-Aronsson, M. Nilsson, Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res. 67, 7512–7517 (2007)

    Article  CAS  PubMed  Google Scholar 

  20. B. Meller, E. Gaspas, W. Deisting, B. Czarnocka, M. Baehre, B.E. Wenzel, Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway. Eur. J. Nucl. Med. Mol. Imaging 35, 1204–1212 (2008)

    Article  CAS  PubMed  Google Scholar 

  21. C. Lundh, M.M. Nordén, M. Nilsson, E. Forssell-Aronsson, Reduced iodine transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J. Nucl. Med. 48, 481–486 (2007)

    CAS  PubMed  Google Scholar 

  22. C. Lundh, U. Lindencrona, P. Postgård, T. Carlsson, M. Nilsson, E. Forssell-Aronsson, Radiation-induced thyroid stunning: differential effects of 123I, 131I, 99mTc and 211At on iodide transport and NIS mRNA expression in cultured thyroid cells. J. Nucl. Med. 50, 1161–1167 (2009)

    Article  CAS  PubMed  Google Scholar 

  23. F.A. Verburg, R.B. Verkooijen, M.P. Stokkel, J.W. van Isselt, The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin 48, 138–142 (2009)

    Article  CAS  PubMed  Google Scholar 

  24. J.C. Sisson, A.M. Avram, S.A. Lawson, P.G. Gauger, G.M. Doherty, The so-called stunning of thyroid tissue. J. Nucl. Med. 47, 1406–1412 (2006)

    CAS  PubMed  Google Scholar 

  25. Y. Yin, Q. Mao, S. Chen, N. Li, X. Li, Y. Li, A quantitative study about thyroid stunning after diagnostic whole-body scanning with 74 MBq 131I in patients with differentiated thyroid carcinoma. Q. J. Nucl. Med. Mol. Imaging 59, 455–461 (2015)

    CAS  PubMed  Google Scholar 

  26. T. Krohn, P.T. Meyer, C. Ocklenburg, D. Knollmann, B. Nowak, W.M. Schaefer, Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance. Nuklearmedizin 47, 248–254 (2008)

    Article  CAS  PubMed  Google Scholar 

  27. O. Sabri, M. Zimny, M. Schreckenberger, A. Meyer-Oelmann, P. Reinartz, U. Buell, Does thyroid stunning exist? A model with benign thyroid disease. Eur. J. Nucl. Med. 27, 1591–1597 (2000)

    Article  CAS  PubMed  Google Scholar 

  28. E. Wudel, K. Koppenhagen, The stunned thyroid? Veränderte Radiojodkinetik der NACH-THERAPIE bei benignen Schilddrüsenerkrankungen. Nuklearmedizin 34, A166 (1995). (Abstract)

    Google Scholar 

  29. M. Dietlein, J. Dressler, W. Eschner, M. Lassmann, B. Leisner, C. Reiners, H. Schicha, Procedure guideline for radioiodine test (version 3). Nuklearmedizin 46, 198–202 (2007)

    Article  CAS  PubMed  Google Scholar 

  30. M. Dietlein, J. Dressler, F. Grünwald, B. Leisner, E. Moser, C. Reiners, H. Schicha, P. Schneider, O. Schober, Guideline for radioiodine therapy for benign thyroid disease (version 4). Nuklearmedizin 46, 220–223 (2007)

    Article  CAS  PubMed  Google Scholar 

  31. L.D. Marinelli, Dosage determination in the use of radioactive isotopes. J. Clin. Invest. 28, 1271–1280 (1949)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. F.A. Leger, M. Izembart, F. Dagousset, L. Barritault, G. Baillet, A. Chevalier, J. Clerc, Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur. J. Nucl. Med. 25, 242–246 (1998)

    Article  CAS  PubMed  Google Scholar 

  33. H.M. Park, Y.H. Park, X.H. Zhou, Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 7, 277–280 (1997)

    Article  CAS  PubMed  Google Scholar 

  34. T.E. Hilditch, M.F. Dempsey, A.A. Bolster, R.M. McMenemin, N.S. Reed, Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur. J. Nucl. Med. 29, 783–788 (2002)

    Article  CAS  Google Scholar 

  35. H.M. Park, O.W. Perkins, J.W. Edmondson, R.B. Schnute, A. Manatunga, Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131. Thyroid 4, 49–54 (1994)

    Article  CAS  PubMed  Google Scholar 

  36. H.S. Wu, H.H. Hseu, W.Y. Lin, S.J. Wang, Y.C. Liu, Decreased uptake after fractionated ablative doses of iodine-131. Eur. J. Nucl. Med. Mol. Imaging 32, 167–173 (2005)

    Article  CAS  PubMed  Google Scholar 

  37. H.W. Yeung, J.L. Humm, S.M. Larson, Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J. Nucl. Med. 41, 1082–1085 (2000)

    CAS  PubMed  Google Scholar 

  38. J.C. Reynolds, J. Robbins, The changing role of radioiodine in the management of differentiated thyroid cancer. Semin. Nucl. Med. 27, 153–164 (1997)

    Article  Google Scholar 

  39. E.C.S.C. Etchebehere, A.O. Santor, P.S. Matos, L.V.M. Assumpçāo, Lima MCVL, M.C.L. Lima, L.S. Ward, Is thyroid stunning clinically relevant? A retrospective analysis of 208 patients. Arq. Bras. Endocrinol. Metab. 58, 292–300 (2014)

    Article  Google Scholar 

  40. T. Bajén, S. Mañé, A. Muñoz, J.R. García, Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J. Nucl. Med. 41, 2038–2042 (2000)

    PubMed  Google Scholar 

  41. I.R. McDougall, 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl. Med. Commun. 18, 505–512 (1997)

    Article  CAS  PubMed  Google Scholar 

  42. E.B. Silberstein, Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J. Nucl. Med. 48, 1043–1046 (2007)

    Article  CAS  PubMed  Google Scholar 

  43. N.A. Damle, C. Bal, S. Ballal, Stunning in post (131)I therapy scans after low-dose (131)I diagnostic whole body scans with differentiated thyroid cancer in the Indian patient population: critical importance of interval between the two scans. Indian J. Endocrinol. Metab. 16, 477–478 (2012)

    Article  PubMed  PubMed Central  Google Scholar 

  44. R.K. Jeevanram, D.H. Shah, S.M. Sharma, R.D. Ganatra, Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Int. J. Rad. Appl. Instrum. B. 13, 277–279 (1986)

    Article  CAS  PubMed  Google Scholar 

  45. M. Medvedec, Thyroid stunning in vivo and in vitro. Nucl. Med. Commun. 26, 731–735 (2005)

    Article  PubMed  Google Scholar 

  46. J. Halstenberg, W.T. Kranert, H. Korkusuz, A. Mayer, H. Ackermann, F. Grünwald, C. Happel, Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves’ disease. Nuklearmedizin 57, 43–49 (2018)

    Article  PubMed  Google Scholar 

  47. M.K. Chen, M. Yasrebi, J. Samii, L.H. Staib, I. Doddamane, D.W. Cheng, The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid 22, 304–309 (2012)

    Article  CAS  PubMed  Google Scholar 

  48. A. Siddiqi, R.R. Foley, K.E. Britton, A. Sibtain, P.N. Plowman, A.B. Grossman, J.P. Monson, G.M. Besser, The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin. Endocrinol. (Oxf.). 55, 515–521 (2001)

    Article  CAS  PubMed  Google Scholar 

  49. M. Ruhlmann, W. Sonnenschein, J. Nagarajah, I. Binse, K. Herrmann, W. Jentzen, Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities. Nucl. Med. Commun. 39, 457–464 (2018)

    Article  CAS  PubMed  Google Scholar 

  50. P. Szumowski, M. Mojsak, S. Abdelrazek, M. Sykała, A. Amelian-Fiłonowicz, D. Jurgilewicz, J. Myśliwiec, Calculation of therapeutic activity of radioiodine in Graves’ disease by means of Marinelli’s formula, using technetium (99mTc) scintigraphy. Endocrine 54, 751–756 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. K. Watanabe, T. Igarashi, H. Ashida, S. Ogiwara, T. Ohta, M. Uchiyama, H. Ojiri. Diagnostic value of ultrasound and Tl-201/Tc-99m dual scintigraphy in differentiating between benign and malignant thyroid nodules. Endocrine (2018). https://doi.org/10.1007/s12020-018-1768-0

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Frankfurt, Theodor Stern Kai 7, D-60590, Frankfurt, Germany

    Christian Happel, Wolfgang Tilman Kranert, Benjamin Bockisch, Daniel Gröner & Frank Grünwald

  2. Institute for Biostatistics, University Hospital Frankfurt, Theodor Stern Kai 7, D-60590, Frankfurt, Germany

    Hanns Ackermann

  3. Department of Nuclear Medicine, University Hospital Essen, Hufelandstraße 55, D-45147, Essen, Germany

    Ina Binse & Ken Herrmann

Authors
  1. Christian Happel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Tilman Kranert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanns Ackermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ina Binse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Benjamin Bockisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniel Gröner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ken Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Frank Grünwald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Happel.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Happel, C., Kranert, W.T., Ackermann, H. et al. Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases. Endocrine 63, 537–544 (2019). https://doi.org/10.1007/s12020-018-01833-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-018-01833-5

Keywords

Search

Navigation